Advisory - One lot of pms-PROGESTERONE 100 mg capsules recalled because it may pose serious risks to individuals with severe peanut allergies
OTTAWA, ON, Aug. 24, 2021 /CNW/ -
Summary
Product: pms-PROGESTERONE 100 mg capsules (DIN 02476576) Issue: Pharmascience Inc. is recalling one lot (1318593, expiry 10/2022) of pms-PROGESTERONE 100 mg capsules because the bottles may contain capsules from another manufacturer, Akorn 100 mg progesterone capsules. The Akorn capsules contain peanut oil, which poses serious risks to individuals with severe peanut allergies. Akorn 100 mg progesterone is not authorized for sale in Canada. The pms-PROGESTERONE 100 mg capsules are round and beige with "100" printed in black on the capsule, while the Akorn 100 mg progesterone capsules are round and pink with "AK" printed in black on the capsule.
What to do:
If you have severe peanut allergies, stop using your medication and return it to the pharmacy to get a replacement bottle.
If you do NOT have peanut allergies and you find any Akorn progesterone capsules (pink marked with "AK"), return your bottle to the pharmacy for disposal of the Akorn progesterone doses and to receive replacement doses of pms-PROGESTERONE.
Issue Pharmascience Inc. is recalling one lot (1318593, expiry 10/2022) of pms-PROGESTERONE 100 mg capsules because the bottles may contain Akorn 100 mg progesterone gelatin capsules in addition to or instead of the intended pms-PROGESTERONE 100 mg gelatin capsules. The Akorn capsules contain peanut oil, an ingredient that is not listed on the label of pms-PROGESTERONE 100 mg capsules. Peanuts may cause life-threatening allergic reactions (anaphylaxis) in individuals with severe peanut allergies.
pms-PROGESTERONE is a prescription hormone drug used as part of hormone replacement therapy for menopause in women.
The pms-PROGESTERONE 100 mg capsules are round and beige with "100" printed in black on the capsule, while the Akorn 100 mg progesterone capsules are round and pink with "AK" printed in black on the capsule.
The Pharmascience and Akorn capsules contain the same dose of the active ingredient, progesterone. Akorn 100 mg progesterone capsule is not authorized for sale in Canada and therefore it has not been reviewed by Health Canada for its safety, efficacy and quality.
Health Canada is monitoring the recall. If additional safety information is identified, Health Canada will take appropriate action and inform Canadians as needed.
Affected products
Company
Product
DIN
Lot
Expiry
Pharmascience Inc.
pms-PROGESTERONE 100 mg capsules
100-capsule bottles
02476576
1318593
10/2022
What you should do
If you have severe peanut allergies, stop using your medication and return it to the pharmacy to get a replacement bottle.
If you do NOT have peanut allergies and if you find any Akorn progesterone capsules (pink marked with "AK"), return your bottle to the pharmacy for disposal of the Akorn progesterone doses and to receive replacement doses of pms-PROGESTERONE.
Consult a health care professional if you have used these products and have health concerns.
Contact Pharmascience Inc. by calling, toll-free, 1-800-340-9735, or by email at [email protected] if you have questions about the recall.
At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided:
Resolution in accordance with the Board's proposed dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the...
TimelyCare, higher education's most trusted virtual health and well-being provider, has earned recognition as one of the World's Best Digital Health Companies by Newsweek, and has been awarded five Top Workplaces Awards for culture excellence....
Avanos Medical, Inc. will webcast its conference call discussing financial results and business highlights for the first quarter 2024 on Thursday, May 2 at 9 a.m., ET. The company will issue a news release detailing its results before the market...
Beijing Avistone Biotechnology Co., Ltd. (also referred to as Avistone Biotechnology or Avistone), an innovative biotechnology company focused on precision oncology therapeutics, announced the approval to expand the use of vebreltinib (also referred...
Through its 2030 Strategic Plan, NJII plans to double the size of the organization and to exceed $70M revenue as it rolls out various new initiatives focused on accelerating technology translation, spurring innovation and upskilling workers. As...
ScreenPoint Medical, today announced a significant transition in its leadership as Mark Koeniguer, the current CEO, steps down from his position. Mark served as CEO since 2022 and was instrumental in ScreenPoint's commercial growth and success over...